Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.

• Authors: RÁČIL Zdeněk; KLAMOVÁ Hana; VOGLOVÁ Jaroslava; FABER Edgar; RÁZGA Filip; ŽÁČKOVÁ Daniela; BUREŠOVÁ Lucie; CETKOVSKÝ Petr; MAYER Jiří
• Year of publication: 2010
• Type: Article in Periodical
• Magazine / Source: American Journal of Hematology
• MU Faculty or unit: Faculty of Medicine
• Field: Oncology and hematology
• Keywords: persistent splenomegaly; CML; CHR
• Description: Splenomegaly belongs among typical findings on physical examination in patients with newly diagnosed chronic myelogenous leukemia (CML). Its disappearance is a part of achieving complete hematological response (CHR), that is nowadays (when second generation of tyrosine kinase inhibitors are available) of particular interest during imatinib treatment.

Related projects

• Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies